• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medication are ineffective. Personalized treatment may be the solution.

Cue is a digital intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions that improve mental health. We analyzed the best-fitting personalized ML models for each individual using Shapley values to determine their feature predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is the leading cause of mental illness across the world.1 Yet only half of those suffering from the condition receive treatment. To improve outcomes, clinicians must be able identify and treat patients who are the most likely to benefit from certain treatments.

The ability to tailor depression treatment guidelines treatments is one way to do this. By using sensors for mobile phones, an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavior predictors of response.

To date, the majority of research on factors that predict depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographics like gender, age and education as well as clinical aspects like severity of symptom and comorbidities, as well as biological markers.

While many of these aspects can be predicted by the information in medical records, very few studies have employed longitudinal data to study the causes of mood among individuals. Many studies do not take into consideration the fact that mood can vary significantly between individuals. Therefore, it is essential to develop methods that permit the determination of individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify various patterns of behavior and emotions that are different between people.

In addition to these methods, the team also developed a machine-learning algorithm that models the dynamic factors that determine a person's depressed mood. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype has been correlated with CAT DI scores that are a psychometrically validated symptoms severity scale. However the correlation was not strong (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1, but it is often not properly diagnosed and treated. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many people from seeking help.

To help with personalized treatment, it is important to identify predictors of symptoms. However, the current methods for predicting symptoms depend on the clinical interview which has poor reliability and only detects a tiny number of symptoms that are associated with depression.2

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements. They also capture a variety of unique behaviors and activity patterns that are difficult to record through interviews.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were referred to online assistance or in-person clinics according to the severity of their depression. Those with a score on the CAT DI of 35 65 were allocated online support via the help of a peer coach. those with a score of 75 were routed to clinics in-person for psychotherapy.

At baseline, participants provided the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included age, sex, and education, marital status, financial status as well as whether they divorced or not, current suicidal ideas, intent or attempts, and how often they drank. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. The CAT-DI assessment was conducted every two weeks for participants who received online support and weekly for those who received in-person support.

Predictors of the Reaction to Treatment

Research is focusing on personalized depression treatment. Many studies are focused on identifying predictors, which will help doctors determine the most effective drugs to treat each individual. In particular, pharmacogenetics identifies genetic variants that determine how to treat depression and anxiety the body metabolizes antidepressants. This lets doctors choose the medications that are likely to be the most effective for each patient, while minimizing time and effort spent on trials and errors, while avoiding any side negative effects.

Another approach that is promising is to create prediction models combining clinical data and neural imaging data. These models can be used to determine which variables are the most predictive of a particular outcome, like whether a non drug treatment for depression will help with symptoms or mood. These models can be used to determine the patient's response to an existing treatment and help doctors maximize the effectiveness of the current treatment.

A new generation of machines employs machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and improve predictive accuracy. These models have shown to be useful in predicting treatment outcomes such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely become the standard of future medical practice.

In addition to ML-based prediction models The study of the mechanisms that cause depression continues. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One way to do this is to use internet-based interventions that offer a more individualized and tailored experience for patients. For instance, one study discovered that a web-based treatment was more effective than standard care in alleviating symptoms and ensuring a better quality of life for patients with MDD. A controlled study that was randomized to an individualized treatment for depression found that a significant number of patients saw improvement over time as well as fewer side consequences.

Predictors of side effects

A major obstacle in individualized depression treatment involves identifying and predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients are prescribed various drugs before they find a drug that is effective and tolerated. Pharmacogenetics is an exciting new method for an efficient and specific approach to selecting antidepressant treatments.

There are a variety of variables that can be used to determine the antidepressant to be prescribed, such as gene variations, phenotypes of patients such as gender or ethnicity, and the presence of comorbidities. To identify the most reliable and reliable predictors for a particular treatment, controlled trials that are randomized with larger samples will be required. This is because it could be more difficult to identify moderators or interactions in trials that comprise only a single episode per person rather than multiple episodes over time.

Furthermore, the prediction of a patient's reaction to a particular medication will likely also require information on symptoms and comorbidities as well as the patient's previous experience of its tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables appear to be reliably associated with response to MDD, such as gender, age race/ethnicity, SES, BMI, the presence of alexithymia and the severity of depressive symptoms.

Many challenges remain in the application of pharmacogenetics for depression treatment. First it is necessary to have a clear understanding of the underlying genetic mechanisms is required, as is a clear definition of what is the best treatment for anxiety and depression treatment cbt - www.Longisland.com, is a reliable indicator of treatment response. Ethics like privacy, and the responsible use of genetic information should also be considered. In the long run, pharmacogenetics may be a way to lessen the stigma associated with mental health treatment and improve the outcomes of those suffering with atypical depression treatment. Like any other psychiatric treatment, it is important to carefully consider and implement the plan. At present, the most effective course of action is to offer patients various effective depression medication options and encourage them to talk freely with their doctors about their experiences and concerns.